Switching from originator rituximab (Rituxan, Genentech) to rituximab-abbs (Truxima, Teva) can save an institution up to $13,000 annually per patient while maintaining efficacy and safety, according to two new studies.
“The findings provide important real-world evidence and should help physicians build confidence in the clinical equivalence of biosimilar rituximab,” said Sandra Cuellar, PharmD, a clinical ambulatory pharmacist and clinical associate professor of pharmacy practice at